Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Factor Receptor-Activating Mutations

Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Factor Receptor-Activating Mutations

November 1st, 2010

Bibliographic Details
Main Authors:	Lazzara, Matthew J. (Contributor), Lane, Keara M. (Contributor), Chan, Richard (Author), Jasper, Paul J. (Author), Sorger, Peter K. (Author), Neel, Benjamin G. (Author), Yaffe, Michael B (Author), Jacks, Tyler E (Author), Lauffenburger, Douglas A (Author)
Other Authors:	Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Yaffe, Michael B. (Contributor), Jacks, Tyler E. (Contributor), Lauffenburger, Douglas A. (Contributor)
Format:	Article
Language:	English
Published:	American Association for Cancer Research, 2012-10-11T17:34:10Z.
Subjects:	Article
Online Access:	Get fulltext

Similar Items

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
by: Heng Sun, et al.
Published: (2018-06-01)

An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)

Corrigendum to: Off‐target inhibition by active site‐targeting SHP2 inhibitors
by: Ryouhei Tsutsumi, et al.
Published: (2019-12-01)

The role of Shp2 in cells response to extracellular physical properties
by: Hsin-Chang Lee, et al.
Published: (2012)

Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
by: Mi Seong Kim, et al.
Published: (2020-01-01)

The Study of Shp2 Activation in Cell Adhesion
by: Chih-Chiang Chou, et al.
Published: (2012)

The biological importance of Shp2 activation for podocyte function
by: Ting-Wei Lin, et al.
Published: (2016)

Phosphatase Shp2 regulates biogenesis of small extracellular vesicles by dephosphorylating Syntenin
by: Yuefei Zhang, et al.
Published: (2021-03-01)

Structural Basis for the Inhibition of Cyclin G‐Associated Kinase by Gefitinib
by: Dr. Naomi Ohbayashi, et al.
Published: (2018-09-01)

Molecular mechanism of gefitinib-induced apoptosis through epidermal growth factor receptor independent pathway
by: Yu, Sheng-Yi, et al.
Published: (2010)

Effect of Sialylation on EGFR Function and Resistance to Tyrosine Kinase Inhibitor Gefitinib
by: Hsin-Yung Yen, et al.
Published: (2014)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan Ying, et al.
Published: (2012-11-01)

Activated Protein Kinase C (PKC) is Persistently Trafficked with Epidermal Growth Factor (EGF) Receptor
by: Carol A. Heckman, et al.
Published: (2020-09-01)

Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.
by: Hanna Björkelund, et al.
Published: (2011-01-01)

Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib
by: Beatrice Copps, BSc, et al.
Published: (2020-03-01)

Acidic extracellular pH promotes activation of integrin α(v)β(3).
by: Ranjani K Paradise, et al.
Published: (2011-01-01)

Acidic Extracellular pH Promotes Activation of Integrin [alpha]v[beta]3
by: Paradise, Ranjani K., et al.
Published: (2011)

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
by: Ricardo A. P. Pádua, et al.
Published: (2018-10-01)

Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1
by: Jung-Chen Su, et al.
Published: (2018-01-01)

Grb2 binding induces phosphorylation-independent activation of Shp2
by: Chi-Chuan Lin, et al.
Published: (2021-04-01)

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
by: Jeffrey C Lee, et al.
Published: (2006-12-01)

MECHANISMS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE ACTIVATION AND NUCLEAR TRAFFICKING
by: Red Brewer, Monica
Published: (2009)

Signalling via integrins and mitogen activated protein kinase in human epidermal keratinocytes
by: Haase, Ingo
Published: (2001)

Microfluidic Concentration-Enhanced Cellular Kinase Activity Assay
by: Lee, Jeong Hoon, et al.
Published: (2010)

Analysis of the SHP2 enhancer for the use of tissue specific activation tagging in Arabidopsis thaliana
by: Antonio Chalfun-Junior, et al.
Published: (2006-01-01)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
by: Fengqi Xiao, et al.
Published: (2020-11-01)

Quantitative modeling perspectives on the ErbB system of cell regulatory processes
by: Lazzara, Matthew J., et al.
Published: (2010)

Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.
by: Asma Beldi-Ferchiou, et al.
Published: (2017-01-01)

Combination of gefitinib and AZD6244 overcomes acquired gefitinib resistance and enhances anticancer effect in lung adenocarcinoma cells harboring an activating EGFR mutation
by: Ya-Ju Chuang, et al.
Published: (2011)

Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro
by: Wei WEI, et al.
Published: (2009-01-01)

Epidermal growth factor receptor inhibition with Gefitinib does not alter lung responses to mechanical ventilation in fetal, preterm lambs.
by: T Brett Kothe, et al.
Published: (2018-01-01)

Comprehensive Model for Epidermal Growth Factor Receptor Ligand Binding Involving Conformational States of the Extracellular and the Kinase Domains
by: Tímea Hajdu, et al.
Published: (2020-08-01)

Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
by: Chris Jopling, et al.
Published: (2007-12-01)

The Phosphatase SHP-2 Activates HIF-1α in Wounds In Vivo by Inhibition of 26S Proteasome Activity
by: Yvonn Heun, et al.
Published: (2019-09-01)

CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non‐small cell lung cancer in vitro and in vivo
by: Kun Zhang, et al.
Published: (2020-06-01)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
by: Amit Joshi, et al.
Published: (2018-01-01)

Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib
by: Miyong Yun, et al.
Published: (2014-08-01)

Platelet nitric oxide synthase is activated by tyrosine dephosphorylation: Possible role for SHP-1 phosphatase.
by: Naseem, Khalid M., et al.
Published: (2009)

PLCβ1-SHP-2 complex, PLCβ1 tyrosine dephosphorylation and SHP-2 phosphatase activity: a new part of Angiotensin II signaling?
by: Rossi Gian, et al.
Published: (2011-06-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)